Solo Scope Colonoscope System

K261015 · Gi View, Ltd. · FDF · Aug 21, 2026 · Gastroenterology, Urology

Device Facts

Record IDK261015
Device NameSolo Scope Colonoscope System
ApplicantGi View, Ltd.
Product CodeFDF · Gastroenterology, Urology
Decision DateAug 21, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 876.1500
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The Solo Scope Colonoscope System is intended to provide visualization (via a video monitor) and diagnostic/therapeutic access to the adult lower gastrointestinal tract, (including but not limited to, the anus, rectum, sigmoid colon, transverse colon, cecum and ileocecal valve) for endoscopy. The Solo Scope Disposable colonoscope is a single use disposable endoscope and cannot be reprocessed.

Device Story

Solo Scope Colonoscope System is a flexible endoscope for lower GI tract visualization and access. System comprises a video controller and a single-use, disposable colonoscope. Colonoscope features a deflectable distal tip with optics, irrigation, insufflation, lens washing, and suction channels. Physician operates the device using handle-mounted angulation knobs and buttons, or a touchscreen on the video controller. The system includes a physician-controlled adjustable stiffness mechanism for the insertion tube. The device provides real-time video output to a monitor, assisting clinicians in diagnostic and therapeutic procedures. Single-use design eliminates reprocessing requirements. System performance is comparable to conventional colonoscopes.

Clinical Evidence

No clinical data. Substantial equivalence supported by bench testing, including software verification/validation, cybersecurity testing, electrical safety/EMC, biocompatibility, mechanical testing, optical/colorimetric testing, and environmental/shelf-life testing.

Technological Characteristics

System includes a video controller and disposable colonoscope. Controller uses Nvidia AGX Orin processor running L4T (Ubuntu-based). Colonoscope features a physician-controlled adjustable stiffness mechanism. Connectivity includes touchscreen and handle-based user controls. Sterilization is not specified, but the colonoscope is single-use. Testing includes electrical safety, EMC, and biocompatibility.

Indications for Use

Indicated for adult patients (22 years and older) requiring visualization and diagnostic/therapeutic access to the lower gastrointestinal tract.

Regulatory Classification

Identification

An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.

Special Controls

*Classification* —(1)*Class II (special controls).* The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.

In combination with the general controls of the FD&C Act, the integrated operating table-electromechanical surgical system is subject to the following special controls: 1. (1) Premarket clinical performance testing, or a combination of premarket clinical performance testing and postmarket surveillance (in accordance with special control (2)), must include the following: 1. (i) Objective performance measures (e.g., rate and number of conversions to other surgical modalities, rate of device related adverse events (including tissue injury, hematoma, and increased blood loss), and their severity, cause, and outcomes) must be reported with relevant descriptive comparator performance measures. 2. (ii) The data must demonstrate the performance of the device for providing accurate and precise control of attached surgical instruments in range of clinical conditions relevant to the device's intended use. 3. (iii) The test dataset must include data collected from a patient population representative of the intended patient population under anticipated conditions of use. 2. (2) Data obtained from postmarket surveillance must demonstrate, in consideration of the premarket data obtained in accordance with special control (1), that the device performs in accordance with special control (1), unless FDA determines, based on the totality of the premarket data, that data from postmarket surveillance is not required to demonstrate that the device performs as intended. Such postmarket surveillance must be conducted per a protocol determined appropriate by FDA to demonstrate that the device performs as intended (in consideration of the premarket data obtained in accordance with special control (1)), and must include initiation, enrollment, and reporting requirements to ensure timely periodic updates to FDA on post-market surveillance progress and outcomes. 3. (3) Animal performance testing must evaluate the extent of port site trauma due to repositioning of table during surgical procedures when utilizing robotic minimally invasive and laparoscopic approaches 4. (4) The device manufacturer must develop, and update as necessary, a device-specific use training program that ensures proper device setup/use/shutdown, accurate control of instruments to perform the intended surgical procedures, troubleshooting and handling during unexpected events or emergencies, and safe practices to mitigate use error. 5. (5) The device manufacturer may only distribute the device to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program. (6) Human factors assessment must demonstrate that the user can correctly use the device system across all intended use environments with the provided instructions and training materials, including patient access during normal operating conditions and emergency situations, and effects arising from the integrated nature of the operating table and robotic surgical arms. (7) Labeling must include: (i) A detailed summary of clinical performance testing conducted with the device, including study population, results, adverse events, and comparisons to any comparator groups identified; (ii) A statement in the labeling that the safety and effectiveness for the representative specific procedures was based on evaluation of the device as a surgical tool and did not include evaluation of outcomes related to the treatment of the patient's underlying disease or condition, unless FDA determines that it can be removed or modified based on clinical performance data submitted to FDA; (iii) Identification of compatible devices; (iv) The list of surgical procedures for which the device has been determined to be safe with clinical justification; (v) Reprocessing instructions for reusable components; (vi) A shelf life for any sterile components; (vii) A description of the device-specific use training program; (viii) A statement that the device is only for distribution to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program; and (ix) A summary of any completed postmarket surveillance data collected as required by special control (2), including updated labeling to accurately reflect outcomes observed in postmarket surveillance. (8) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and must include: (i) Device motion accuracy and repeatability; (ii) System testing; (iii) Instrument reliability; (iv) Crosstalk; (v) Table motion control; (vi) Thermal effects on tissue; (vii) User-device interface performance; (viii) Workspace access testing; and (ix) Performance testing with compatible devices. (9) Software verification, validation, and hazard analysis must be performed. (10) Electromagnetic compatibility and electrical, thermal, and mechanical safety testing must be performed. (11) Performance data must demonstrate the sterility of all patient-contacting device components. (12) Performance data must support the shelf life of the device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life. (13) Performance data must validate the reprocessing instructions for the reusable components of the device. (14) Performance data must demonstrate that all patient-contacting components of the device are biocompatible. (15) Performance data must demonstrate that all patient-contacting components of the device are non-pyrogenic. (16) The device manufacturer must submit a report to the FDA annually on the anniversary of initial marketing authorization for the device, until such time as FDA may terminate such reporting, which comprises the following information: (i) Cumulative summary, by year, of complaints and adverse events since date of initial marketing authorization; and (ii) Identification and rationale for changes made to the device, labeling, or device specific use training program, which did not require submission of a premarket notification during the reporting period.

Predicate Devices

Submission Summary (Full Text)

{0} FDA U.S. FOOD & DRUG ADMINISTRATION August 21, 2026 Gi View, Ltd. % Amit Goren RA Consultant A. Stein - Regulatory Affairs Consulting , Ltd. 18 Hataas St. (Suite 19) Kfar Saba, 4442518 Israel Re: K261015 Trade/Device Name: Solo Scope Colonoscope System Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope And Accessories Regulatory Class: Class II Product Code: FDF, FET Dated: July 21, 2026 Received: July 21, 2026 Dear Amit Goren: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K261015 - Amit Goren Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K261015 - Amit Goren Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, SIVAKAMI VENKATACHALAM -S *for* Shanil P. Haugen, Ph.D. Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K261015 | ? | | Please provide the device trade name(s). | | ? | | Solo Scope Colonoscope System | | | | Please provide your Indications for Use below. | | ? | | The Solo Scope Colonoscope System is intended to provide visualization (via a video monitor) and diagnostic/therapeutic access to the adult lower gastrointestinal tract, (including but not limited to, the anus, rectum, sigmoid colon, transverse colon, cecum and ileocecal valve) for endoscopy. The Solo Scope Disposable colonoscope is a single use disposable endoscope and cannot be reprocessed. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | | Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☐ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | ? | {4} K261015 Page 1 of 5 [LOGO] Solo Scope Colonoscope System - 510(k) Submission 510(k) Summary ### 510(K) SUMMARY ### SOLO SCOPE COLONOSCOPE SYSTEM ### 510(k) Number K261015 **Applicant Name:** Company Name: GI-View Ltd. Address: 5 Shoham St. Ramat Gan, 5251001 Israel Tel: +972-58-4534373 E-mail: oded@giview.com **Contact Person:** Official Correspondent: Amit Goren Company Name: A. Stein – Regulatory Affairs Consulting Ltd. Address: 18 Hata'as Str., Kfar Saba 4442518, Israel Tel: + 972-9-7670002 Fax: +972-9-7668534 E-mail: amit@asteinrac.com **Date Prepared:** April 21, 2026 **Trade Name:** Solo Scope Colonoscope System **Classification Name:** 21 CFR 876.1500 **Product Codes:** FDF, FET **Classification:** Class II **Predicate Device:** The subject device is substantially equivalent to the following predicate device: | Manufacturer | Device | 510(k) No. | | --- | --- | --- | | GI-View Ltd. | Aer-O-Scope Colonoscope System | K230588 | {5} K261015 Page 2 of 5 ![img-0.jpeg](img-0.jpeg) # *Solo Scope Colonoscope System - 510(k) Submission 510(k) Summary*--- # **Device Description:** The Solo Scope Colonoscope System consists of a video controller and a disposable, single-use colonoscope. Like the predicate, the Solo Scope Colonoscope System is a long flexible endoscope with optics at the deflectable tip of the device and openings for irrigation, insufflation, lens washing, and suction. The Solo Scope’s Video Controller controls the Solo Scope Colonoscope according to user command inputs via either a touchscreen (on the Video Controller) or buttons on the colonoscope handle. The distal tip is deflectable and controlled by angulation knobs on the handle. The device maintains insertion behavior, handling, and performance characteristics comparable to conventional colonoscopes. The colonoscope unit is intended for single use, eliminating the need for colonoscope reprocessing. # **Intended Use/Indication for Use:** The Solo Scope Colonoscope System is intended to provide visualization (via a video monitor) and diagnostic/ therapeutic access to the adult lower gastrointestinal tract (including but not limited to the anus, rectum, sigmoid colon, transverse colon, cecum, and ileocecal valve) for endoscopy. The Solo Scope Disposable colonoscope is a single-use, disposable endoscope and cannot be reprocessed. The intended use is identical to that of the predicate device. # **Technological Characteristics and Comparison to Predicate:** The Solo Scope Colonoscope System shares the same intended use and indications for use as the predicate Aer-O-Scope Colonoscope System and is based on comparable technological principles. Where applicable, comparative testing was conducted against the predicate device to support substantial equivalence. {6} K261015 Page 3 of 5 [LOGO] Solo Scope Colonoscope System - 510(k) Submission 510(k) Summary The subject and predicate devices share comparable technological characteristics, including the same fundamental device components (video controller and disposable colonoscope), mechanism of operation, user interface and operation methods, and applicable safety and performance requirements. The technological differences between the predicate and subject devices include: - Video Controller (VC) core system architecture: - Processor change (Intel-based PC → Nvidia AGX Orin) - Operating system change (Windows → L4T, Ubuntu-based) - Colonoscope design modifications: - Insertion tube variable stiffness mechanism (predefined → physician-controlled adjustable stiffness) - Modifications to mechanical, electro-optical, and packaging components The technological differences do not raise new or different questions of safety or effectiveness. The technological differences were evaluated through comprehensive verification and validation testing, including mechanical, optical, electrical, and software performance testing, as well as biocompatibility and environmental evaluations. The results of these evaluations demonstrate that the subject device meets all predefined acceptance criteria and performs comparably to the predicate device. The methods used to evaluate these differences are consistent with those applied to the predicate device, including biocompatibility, electrical and EMC safety testing, software validation, and bench testing of mechanical and optical performance. The Solo Scope Colonoscope System maintains insertion behavior, handling characteristics, and visualization performance that perform comparably to conventional colonoscopes and within the validated performance envelope of the predicate device. Verification testing was conducted using established methods aligned, to the extent appropriate, with those previously applied to the predicate device. {7} K261015 Page 4 of 5 [LOGO] Solo Scope Colonoscope System - 510(k) Submission 510(k) Summary The evaluation was based on comparable test methodologies and predefined acceptance criteria derived from validated predicate device verification protocols and corresponding performance specifications. The identified technological differences were evaluated through risk-based design controls and verification activities and were determined not to raise new questions of safety or effectiveness. ### Non-Clinical (Bench) Performance Data: The following validation activities were performed: - Software Verification and Validation Testing - Cybersecurity Verification and Validation Testing - Electrical safety and EMC testing - Biocompatibility evaluation - Mechanical Testing - Optical and Colorimetric Testing - Environmental, transportation, and shelf-life Testing All of the validation activities were performed using the same testing techniques and principles as those used with the predicate device. The results of the above-listed validation activities demonstrate that the subject device meets predefined acceptance criteria and supports substantial equivalence to the predicate device. ### Animal Performance Data / Histology Data: Not Applicable ### Clinical Performance Data: Not Applicable ### Conclusions: {8} K261015 Page 5 of 5 [LOGO] Solo Scope Colonoscope System - 510(k) Submission 510(k) Summary Based on the information provided, including bench, software, and safety testing, the Solo Scope Colonoscope System is substantially equivalent to the predicate device, the Aer-O-Scope Colonoscope System (K230588).
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...